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Factors influencing the cost-effectiveness outcomes of HPV vaccination and 
screening interventions in Low-to Middle-Income Countries (LMICs): A 
systematic review  
Abstract 
Background: Cervical cancer ranks fourth amongst the commonest malignancies worldwide 
and the second most prevalent cancer afflicting women in low-to middle-income countries 
(LMICs), hence, of great public health importance. LMICs are the most affected regions as 
evidenced by their high prevalence of the disease. Mortality associated with cervical 
neoplasms is preventable through the implementation of recommended preventive 
approaches.  
Aims: This review aimed at appraising evidence on the cost-effectiveness of cervical cancer 
prevention interventions in LMICs involving cervical screening and HPV vaccination 
programmes.  
Methods: A search of CINAHL, MEDLINE, PubMed, and Web of Science was elicited and 
studies published between 1st January 2008 and 31st December 2018 were retrieved. Two 
authors independently undertook the screening, review, selection of studies, and data 
extraction with disagreements being resolved through discussion and consensus.  
Results: Twelve studies were selected. The cost-effectiveness outcomes of HPV vaccination 
and screening interventions are dependent on age, screening method used, intervention 
coverage, and the number of doses or visits required for vaccination and screening 
respectively. A combination of visual inspection with acetic acid (VIA) screening and HPV 
vaccination appears to be the most cost-effective approach in reducing the lifetime risk for 
HPV-linked cervical neoplasms. Similarly, vaccination as a stand-alone intervention is 
potentially cost effective provided the coverage is maintained between 70-100%.  
Conclusions: HPV vaccination and screening interventions may be cost-effective in LMICs 
and potentially reduce the lifetime risk, economic burden, and associated mortality. However, 
it is important to consider the factors that influence the cost-effectiveness of cervical cancer 
prevention interventions for better outcomes to be realised.  
Key points for decision makers 
▪ HPV vaccination and VIA screening appear to be cost-effective approaches for 
reducing the lifetime risks for cervical cancer in LMICs 
▪ A high loss-to-follow-up for vaccination and screening is associated with increased 
mortality 
▪ Early screening for HPV below the age of 30 years could potentially reduce cervical 
cancer associated morbidity and mortality 
▪ Implementation of organised programmes improves coverage and has better outcomes 





Cervical cancer ranks fourth among the more ubiquitous global malignancies and is the 
second most prevalent cancer afflicting women in low-to middle-income countries (LMICs), 
thus, representing a significant public health challenge (1). It represents an estimated 6.6% of 
all neoplasms in women (2) with over 550,000 new cases and 311,365 fatalities reported in 
2018 (2,3). This figure is higher than the cervical cancer-linked mortality of approximately 
266,000 deaths reported in 2012 (4) and 270,000 deaths recorded in 2015 (5).  
LMICs have a higher burden of cervical carcinoma recording more than two thirds of 
global cases and 90% of all associated deaths (6). Future projections suggest a potential rise 
in cancer cases amongst women by 0.11% in 2035 while that of males will drop by 0.03% 
(7). Despite these facts, countries bearing the highest burden of cervical carcinomas utilize 
only 5% of all resources spent on the disease (5).   
Healthcare systems in most LMICs are fragmented and present many challenges which 
limit women’s access to treatment interventions (5). Many countries lack well organized 
programmes for cervical cancer mitigation with financial constraints further limiting access 
to relevant interventions; thus, , causing up to an 18 times greater mortality rate in 
comparison to developed countries (3). Cervical cancer propagates the cycle of poverty and 
undermines economic development in affected communities.   
An association exists between human papilloma virus (HPV) infections and cervical 
cancer (8), which account for 15.4% of all carcinomas linked to infections within sub-
Saharan Africa (9). There exists clinically effective vaccines against the oncogenic strains of 
HPV (10) but these are not freely available in most LMICs (6). Lack of government 
prioritization in LMICs limits access to life saving preventive interventions for women.   
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Early detection of cervical neoplasms is a major prognostic factor and improves 
women’s survival rate (11). Deaths and disability occasioned by cervical cancer are 
preventable through multidisciplinary and comprehensive interventions delivered across the 
lifespan to ensure their cost-effectiveness (5,12,13). The WHO’s comprehensive approach to 
controlling cervical carcinoma provides for primary, secondary, and tertiary prevention 
measures such as vaccination, screening, and post-treatment follow-up services respectively 
(12,14).    
A quick scoping of existing literature on the current research question retrieved two 
systematic reviews undertaken in LMICs. The first review (15) mainly focussed on HPV 
vaccination with minimal attention paid to screening interventions. Notably, the conclusions 
made by Fesenfeld, Hutubessy, and Jit, (2013) only centred around the implications of model 
types, vaccine prices, and vaccinating boys on cost-effectiveness outcomes. A second 
systematic review (16) focussed on how decision models utilized in HPV vaccination 
programmes account for the apparent challenges in LMICs.  
The evidence regarding the most suitable strategies for preventing cervical neoplasms and 
the specific factors influencing the cost-effectiveness of such interventions is not 
comprehensive. Notably, the preferences for screening or vaccination approaches varies 
across LMICs and consistency in practice appears to be lacking. There is therefore a need to 
consolidate evidence on the interventions and optimize resource allocation for preventing 
cervical neoplasms in LMICs.  
This systematic review (SR) comparatively investigates the factors influencing the cost-
effectiveness outcomes of both screening and vaccination interventions. Furthermore, the 
review appraises the available economic evidence on the cost-effectiveness of HPV screening 
programmes in LMICs not addressed by previously undertaken studies. Lastly, the 
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researchers explore the cost-effectiveness for combining various HPV screening approaches 
with HPV vaccination in LMICs. The findings are of significance to health policy 
formulators as well as health practitioners involved in mitigation of cervical carcinomas.      
Research questions 
1. What factors influence the cost-effectiveness outcomes of HPV vaccination and 
screening in LMICs? 
2. Are HPV screening interventions cost-effective in LMICs? 
3. Which screening approach is the most cost-effective when combined with HPV 





The study adopted a systematic review design in answering the research questions. The 
reporting was undertaken in compliance with the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) statement (17). A protocol for this systematic 
review is available on request through the authors’ email addresses 
(bernardokeah@gmail.com or c.h.ridyard@bangor.ac.uk). 
 Table 1 below outlines the PICOs (Population, Intervention, Control, Outcomes) 
framework that was adopted to facilitate a literature search across databases using appropriate 
medical subject headings (MeSH) (18). The review targeted cost-effectiveness studies 
assessing HPV vaccination and screening in LMICs. Grey literature and unpublished studies 
were excluded from this review to avoid their potential effect on results synthesis (19).  
Table 1: PICOS framework 
Population The population for the HPV vaccination comprised of Girls and boys from 
(low-to-middle income countries (LMICs) aged between 9-15 years. The 
population for cervical cancer screening comprised of women from LMICs 
aged between 20-69 years  
Intervention HPV vaccination and/or routine screening through visual inspection with 
acetic acid (VIA), cytology, or Pap smear 
Control No intervention or vaccination only, or screening only. 
Outcomes i. Reduction in the incidence and mortality associated with cervical 
neoplasms  
ii. Incremental Cost-Effectiveness Ratio (ICER)  
iii. Incremental costs. 
Study 
Design 
Cost-effectiveness analysis studies 
 
CINAHL, MEDLINE, PubMed, and Web of Science were searched between 15th July 
2019 and 25th July 2019. Only studies published in English, between 1st January 2008 and 
31st December 2018 were included. Search terms applied included developing countr*, low-
income countr*, screen*, monitor*, check*, VIA, cervical cancer, cervical neoplasm*, HPV, 
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vaccine*, cost-effective* and cost-utility. Boolean operators ‘OR’ and truncation (*) to were 
useful in expanding the search whereas “AND” was utilized in limiting the searches. 
Appendix 1 below provides the full search strategy and the limiters as applied in the 
MEDLINE database. 
Eligibility assessment commenced with the screening of the article titles after which the 
abstract and the entire article were read to ascertain consistency with the inclusion criteria 
outlined in the PICOS framework. The selection process also entailed an assessment of the 
methodological rigour of the studies.  
A Microsoft excel data extraction sheet was piloted using two randomly selected articles 
and refined based on the pilot outcome (20,21). The extraction process followed a systematic 
process to minimize errors and enhance the quality of the findings. The extracted data was 
checked against the checklist and inclusion criteria to ensure its completeness and accuracy.  
Information extracted included the type of economic evaluation undertaken, the study 
perspective as well as the key assumptions. Additional data included the study population, the 
interventions, and the nature of the study whether model-based or empirical studies. The 
extraction also included the source of the cost measures, costing approach, the reference year, 
type of costs included, benefits accrued, sensitivity analysis undertaken, the cost-
effectiveness threshold, the ICERs, the study conclusions, and the declaration of funding as 
well as any conflicts of interest.   
 The Drummond and the CHEC (consensus on health economics criteria) checklists 
were employed in assessing the risk of bias (RoB) (20,22). The RoB was useful in 
ascertaining any significant variations with respect to the cost-effectiveness of the 
interventions. The assessment also focussed on the transparency and clarity in reporting cost 
components (23). Following the RoB assessment, studies were excluded based on their 
8 
 
transparency. Studies that did not report on the relevant parameters as outlined in the CHEC 
checklist were deemed as lacking transparency and excluded from the review. 
Summary measures included the incremental costs for HPV vaccination and cervical 
cancer screening as well as the ICER (24). Additional measures included the benefits 
reported across studies such as the effect of the interventions on the lifetime risk as well as 
the mortality linked with cervical carcinomas.   
Two authors independently undertook the screening, review, selection of studies, and data 
extraction with disagreements resolved through discussion and consensus. This review 
provides a narrative synthesis of the results and does not constitute a meta-analysis of the 
study findings. The costs and benefits are reported in a uniform currency of international 
dollars (I$) by applying the purchasing power parity exchange rates (25) and discounted at 





The figure 1 below summarizes the process for identifying, screening, and selecting of 






















Figure 1: PRISMA flow chart summarizing the process for selecting studies 
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The literature search yielded 188 studies and 152 studies after deduplication. Following 
title review, 114 studies were excluded whereas a further 11 articles were discarded following 
abstract review. Twelve articles were excluded after full text reading and a further three 
articles excluded after assessing the RoB, reporting transparency, as well as their 
transferability. Finally, this review included twelve (12) studies that met the stated criteria. 
Study characteristics 
The review provided eleven cost-effectiveness analysis (CEA) studies and one cost-utility 
analysis (CUA) study published. All the retrieved studies originated from LMICs namely 
Thailand, Colombia, Uganda, Laos, Malaysia, Iran, China, Honduras, India, South Africa, 
and Brazil as shown in Figure 2. All the retrieved studies were model-based and relied on 
published data for model calibration.  
 
Figure 2: Distribution of selected studies per country 
The studies were modelled on hypothetical participants and their age ranges depended 
on the intervention type. The participants included females aged 9-15 years for the HPV 
vaccination interventions and 21-69 years for screening interventions while one study 
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explored the potential benefit of vaccinating boys. The interventions reported in the included 
studies were HPV vaccination in combination with screening (8,26–29), HPV vaccination 
only (30–33), and screening only (34–36).  
The outcomes of the interventions reported include a reduction in the cervical 
carcinoma incidence, improvement in the quality of life and mortality reduction. The authors 
reported the cost-effectiveness of the interventions by comparing the ICERs with the per 
capita GDP per capita as proposed by the WHO’s Commission for Macroeconomics and 
Health (37–39). Interventions whose ICERs fall below the per capita GDP (1XGDP per 
capita) are highly cost-effective while those that do not surpass two times the GDP (2XGDP) 
are very cost-effective. Lastly, interventions whose ICERs fall below three times the per 
capita GDP (3XGDP per capita) are considered cost-effective. Based on these measures, four 
of the interventions were highly cost-effective whereas half of the interventions surpassed the 
cost-effectiveness threshold, while two did not. 
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Table 2: Summary of study characteristics 
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Campos et al., (35)  Uganda  Women  >35   Screening: 
VIA or HPV 
DNA 
 Model  No screening  YLS  Societal  Cost-
effective 
Declared NCI and 
B&MGF 





10  Vaccination 
plus 
screening 








Ezat and Aljunid (8) Malaysia Women >18 Vaccination 
plus 
screening 








Khatibi et al. (30) Iran Girls 15 Vaccination Model No vaccination 
no screening 




Levin et al. (36) 
 









Molina et al. (33) Honduras Girls 11 Vaccination Model No vaccination, 
no screening 





Prinja et al. (32) India Girls 11 Vaccination Model Treatment of 
unvaccinated 








Sharma et al. (26) 
  
 



















































AUF Agence Universitaire de la Francophonie, B&MGF Bill &Melinda Gates, DALYs Disability-adjusted-life-years, NCI National Cancer Institute, QALYs 
quality-adjusted-life-years, YLS years of life save
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Risk of bias (RoB) within the selected studies 
Table 2 below summarizes the risk of bias assessment using the CHEC checklist as proposed by Wijnen et al., (2016) . 








































et al. (31) 
Vanni et 
al. (29) 
1 Clearly defined population Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
2 Clearly defined comparator Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
3 Research question Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
4 Appropriate design Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
5 Valid assumptions Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
6 Appropriate time horizon Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
7 Perspective chosen Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
8 All costs included Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
9 Appropriate cost measures Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
10 Appropriate cost valuation Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
11 All outcomes identified Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
12 Measured all outcomes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
13 Outcomes valued correctly  Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
14 ICERs/ ICURs calculated Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
15 Discounted costs and benefits Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
16 Sensitivity analysis Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
17 Conclusions linked to results Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
18 Generalizability discussed No No No No No No No No No No No No 
19 Competing interests declared No Yes Yes No No Yes Yes No No Yes Yes No 





There were significant differences across the selected studies, hence, this review 
focussed on describing the results, and their application rather than undertaking a meta-
analysis of key findings. The study population for both screening and vaccination 
interventions was predominantly female while only one study included males (29). The latter 
findings revealed that including males makes HPV vaccination intervention non cost-
effective (29).  
HPV vaccination 
Eleven studies reported vaccinating girls aged 9-13 years was highly cost-effective; 
however, one study found otherwise but assumed a low coverage and a very high cost of 
vaccines (30). Regarding the number of doses required to achieve lifelong immunity against 
HPV, four studies assessed the effectiveness of vaccination with three doses (27,28,30,33). 
Two more studies assessed the use of two doses of vaccination (29,32) while another two 
studies focused on single dose vaccinations (26,31). Determining the number of vaccine 
doses that produced the best cost-effectiveness results was beyond the scope of this review.  
Furthermore, the vaccine efficacy significantly influences cost-effectiveness outcomes 
for vaccination programmes (26,31,32). The findings suggest that HPV vaccination 
interventions have potential cost-effectiveness in LMICs. Vaccination without any other 
intervention appears to be very cost effective (ICER I$3.19-821.85/ QALY/ DALY) provided 
the coverage is maintained between 70-100% based on the reviewed evidence (32,33). 
However, an Iranian-based study determined that three dose vaccination was not cost-






The reported age range for screening was 21-69 years (34), 35 years (35), and 35-45 
years (36). Notably, two of the included studies reported initiating screening at an early age 
(below 30 years) improved cost-effectiveness (28,34). The screening approaches also varied 
across studies and included VIA (26–28,35), HPV DNA testing (26–28,34–36), and 
cytological analysis or Pap smear (8,26–29,34,36). Cost-effectiveness varied significantly 
when drawing comparisons based on the screening approaches used.   
The number of visits required to complete a screening test is important because the 
associated loss-to-follow-up (LTFU) undermines the overall effectiveness of screening 
interventions. HPV DNA analysis appears to be less cost-effective whenever the LTFU 
exceeds 40% of the primary population (28,34). Notably, reducing the uptake of follow-up 
services may contribute to a higher mortality rate in comparison with low coverage with 
respect to screening interventions.  
The reviewed evidence shows that screening interventions may not be cost-effective 
at lower coverage but are cost-effective at 50% coverage and become very attractive options 
at a coverage of 70% of the population at risk. In addition, the findings reveal that organized 
cervical cancer prevention programmes achieve a higher coverage of the population at risk 
than opportunistic programmes and result in better cost-effectiveness outcomes than 
opportunistic interventions (28,34).  
The cost range for VIA screening was I$3.65-I$55.81 whereas HPV DNA testing and 
cytological analysis across costs ranged between I$9.0-I$229.93 and I$3.74-I$69.20 
respectively. The ICERs reported in different studies varied widely with two studies reporting 
that screening with no other intervention was cost-effective (34,35).  The implementation of 




I$105.21/YLS (36). When the loss-to-follow-up is below 40%, HPV DNA testing appears to 
yield higher cost-effectiveness when compared with other methods (35). Otherwise, there is a 
73% probability that VIA will be more cost-effective screening strategy in comparison with 




Table 4: Summary of individual study results 
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USD$44/YLS 9.00 32.74 Very 
cost-
effective 
Campos et al. (35) 
  
VIA 1x 30-100% 40-60% 2005           






Levin et al. (36) 
  
HPV DNA 2x   89.7(50-
100)% 
2005 $45.89 $80-150/YLS 32.19 105.21 Very 
cost-
effective 
Cytology     63(50-
100)% 
  $5.33   3.74     
VACCINATION ONLY 
Khatibi et al. (30) Vaccination 3x 60% 100% 2013 IRR4181805 IRR439000000 251000000-
842000000/ QALY 
148.38 15608.94 Not cost-
effective 
Termrungruanglert 
et al. (31) 





















Prinja et al. (32) Vaccination 2x 70% 93% 2015   I$3.38/DALY 3.19 3.19 Very 
cost-
effective 
VACCINATION AND SCREENING 






1x 80%   2005 I$10-100 I$2260- I$3550/YLS 7.01-70.14 2980.86 Cost-
effective 





HPV DNA 2x >60% 40-60%   I$26.11 I$4250/YLS 18.31   Very 
cost-
effective 
Cytology 3x       I$18.92   13.27   Not cost-
effective 











VIA         $75   55.81     
HPV DNA         $309   229.93     
Cytology         $93   69.20     







Lifelong 2013 I$33.5 I$2544/DALY 29.76 2260.31 Very 
cost-
effective 





















  I$48.27 I$3455/DALY 42.89 3069.72 Cost-
effective 
Ezat and Aljunid 
(8) 
  




Cytology   70(40-
90)% 
    RM41-72 RM947/QALY 8.33-14.64 192.53 Very 
cost-
effective 
Vanni et al. (29) 
  





Cytology   63% 58%             
 
DNA deoxyribonucleic acid, HPV human papilloma virus, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio, DALYs Disability-




HPV vaccination combined with screening 
Combining HPV vaccination with any of the screening approaches potentially results 
in better cost-effectiveness outcomes as reported in four studies when compared with either 
screening only or vaccination only interventions (8,28,29). However, vaccination appears to 
be cost-effective only when combined with either VIA or HPV DNA testing but not in 
combination with cytology (ICER: I$2980.86/ YLS (26).  
Vaccination combined with VIA screening was associated with the highest (85.70%) 
decrease in cervical carcinoma cases (28) whereas two-times HPV DNA testing recorded the 
lowest (26-50%) reduction in cancer cases. When ranked based on the incremental cost-
effectiveness ratios, there is an overlap of the ICERs across the three interventions namely 
screening only (ICERs I$37.4-I$210.41/YLS), vaccination combined with screening (ICERs 
I$192.53-I$8751.21 per QALY/ DALY/ YLS), and vaccination-only interventions (ICERs 
I$3.19-I$15608.94/QALY/ DALY).  
The findings suggest that combining VIA screening and HPV vaccination could be 
the most cost-effective approach in reducing the lifetime risk for cervical neoplasms linked to 
HPV by 85.7% (28). Regarding the approach that could be most cost-efficacious between 
screening interventions and vaccination programmes, probabilistic sensitivity analyses of 
cost-effectiveness results revealed that five yearly screening had a 70-80% probability for 






The results from this review suggest HPV vaccination and screening interventions 
have potential cost-effectiveness in decreasing the lifetime risk as well as mortality (26-
85.7%) associated with cervical carcinoma. The interventions are useful in mitigating the 
huge disease and economic burden caused by HPV infections. Prevention approaches namely 
screening, vaccination, or vaccination combined with screening are potentially cost-effective. 
The interventions become even more cost-effective when screening and vaccination 
programmes are combined. The findings are in tandem with a previous review, which 
reported vaccination only programmes are cost-effective even in settings that lack organized 
screening interventions (15).  
Based on the outcomes of sensitivity analyses conducted across the studies, the 
findings revealed a host of factors that significantly influence the cost effectiveness of either 
screening or HPV vaccination interventions. Key among these factors is the age for 
delivering the vaccination or screening programmes as well as the number of doses or visits 
required for vaccination and screening respectively. With regard to vaccination age, the 
evidence suggests better outcomes with interventions delivered between the age of nine and 
fifteen years. However, there was insufficient evidence to conclude whether the different 
dose schedules influence the cost-effectiveness outcomes for HPV vaccination. Regarding 
screening interventions, two studies  revealed that early screening from twenty years is more 
cost-effective in comparison with screening from thirty years and above (28,34).    
The reviewed evidence also suggests that high coverage for both screening and HPV 
vaccination interventions are critical factors that influence cost-effectiveness outcomes. The 
interventions appear to be less cost-effective at a coverage below 50% of the population at 




findings are inconclusive due to contradictory results from the included studies. One study 
concluded that the sensitivity of the test used has negligible impact on the cost-effectiveness 
outcomes for screening interventions (35) while another contradicted these findings (28). The 
remainder of the studies did not conclude on the impact of the screening test sensitivity on the 
cost-effectiveness results.   
Policy and practice implications 
The findings of this review suggested that implementing organized programmes as 
opposed to opportunistic interventions potentially yields better cost-effectiveness outcomes 
due to improved coverage (28,34). This is consistent with the WHO recommendations 
emphasizing on the need for organized screening and vaccination interventions for better 
outcomes (40). Similarly, evidence from high-income countries demonstrates the importance 
for organized programmes (41).   
The cost-effectiveness of screening and HPV vaccination interventions also depends 
on the screening method used, number of visits required, screening age, coverage, test 
sensitivity and specificity, as well as any follow-up requirements. Generally, any of the three 
screening methods (VIA, HPV DNA testing, and cytological testing or Pap smear) are cost-
effective as a stand-alone intervention. However, combining screening interventions with a 
vaccination programme yields superior cost-effectiveness outcomes. Comparatively, VIA 
seems to be the most cost-effective screening strategy whereas the cytological testing seems 
to be least cost-effective when implemented alone or in combination with HPV vaccination. 
One of the factors that makes VIA significantly more cost-effective than other screening 
methods is its reduced loss-to-follow-up (LTFU) (28,35).  
LTFU is of great importance especially in cases where there are confirmed positives 




applies to HPV vaccination interventions that require women to return to the facility for 
booster doses before attaining full immunity. LTFU increases the mortality rates therefore 
making a particular screening test less cost-effective. Therefore, public health practitioners 
should take into account the potential LTFU when choosing the most suitable screening 
method. In addition, there is need for relevant policy guidelines aimed at reducing the high 
LTFU witnessed in LMICs by opting for screening and HPV vaccination interventions that 
do not require women to frequent the health facility.    
The success of a VIA screening intervention depends on the context and may suffer 
some setbacks caused by cultural barriers that undermine women’s adherence (8). Notably, 
decision makers should have a clear understanding of the contextual factors such as women’s 
preferences regarding the available screening methods. It may be prudent to opt for other 
culturally acceptable interventions that do not discourage women from taking up screening 
such as HPV DNA testing through a self-collection of HPV samples approach (35). Such an 
approach may be more costly when compared with sample collection by healthcare providers 
but useful in overcoming certain cultural barriers to cervical screening (35,42,43).  
The reviewed evidence also suggests that providing screening at an early age of 
twenty (20) years has a higher cost-effectiveness and better outcomes in comparison with 
screening women after they attain 30 years (28),(34). This is important considering the fact 
that most screening interventions target women after attaining 30 years despite the evidence 
showing a peak incidence of HPV infection below this age (6,34).  
Similarly, age influences the cost-effectiveness of immunization programmes 
targeting HPV eradication. Consistent with current evidence (44), this SR affirms that 
immunizing girls at an early age (9-13 years) yields higher benefits in LMICs (26,28,31–33). 




aged 15 years was not a cost-effective option (30). Notably, the latter study lacked country 
data in model calibration, assumed a low coverage and had the highest cost estimates in 
comparison with other studies included in this review. There was also no evidence with 
regard to the potential cost-effectiveness of HPV vaccination in older women.  
Generally, screening and HPV vaccination programmes with higher coverage tend to 
yield better cost-effectiveness outcomes. This is evidenced by the sensitivity analyses 
conducted across the selected studies revealing coverage as a critical factor in cost-
effectiveness of the interventions (8,31,34).  
One of the challenges identified in LMICs is the low coverage of cervical cancer 
prevention interventions (45). The interventions only surpassed the cot-effectiveness 
threshold at higher coverage above 50-70% (28) but this remains an uphill task considering 
the fragile healthcare system in LMICs. As discussed above, increased coverage is achievable 
through the implementation of organised interventions. A case example is Rwanda’s 
vaccination campaign that attained a 93.23% coverage surpassing the recommended 
threshold for immunization programmes (46). Considering the evidence that HPV 
vaccination and screening have potential cost-effectiveness even as stand-alone interventions, 
progressively increasing coverage through organised programmes can significantly reduce 
the risk for cancer and associated deaths.       
The unit cost of vaccines is another key determinant influencing cost-effectiveness 
outcomes for HPV vaccination interventions in LMICs (27,32). For instance, doubling the 
unit price of HPV vaccine in Thailand would make the programme non cost-effective (31). 
Higher costs may limit the coverage of vaccination interventions within the context of 
LMICs. This may also translate to an increase in taxation as well as a rise in out-of-pocket 




cervical carcinoma associated with HPV infections and perpetrates the cycle of poverty in 
impoverished societies.  
Implications for research 
Additional studies are essential in ascertaining whether including males in HPV 
vaccination interventions influences the cost-effectiveness outcomes in LMICs. The evidence 
reviewed was not conclusive on this aspect considering that most included studies never 
incorporated the potential effect of including males during the model calibration process. One 
study reported that vaccinating males is a less attractive option (29) whereas another study 
argued that vaccinating males has no usefulness in settings that have 100% HPV vaccination 
coverage amongst females (31). This contradicts available evidence, which demonstrates that 
inclusion of males is a highly beneficial strategy in decreasing the lifetime risk of HPV 
associated infections (41,47), hence worth further investigating. 
There was no sufficient evidence to conclude whether the number of doses required to 
complete a vaccination programme against HPV influences the cost-effectiveness of 
vaccination interventions. Across all the studies, subjects acquired lifelong immunity upon 
completion of the immunization schedule regardless of the number of doses. It is important to 
note the uncertainty in lifelong immunity considering the fact that there are no lifetime 
studies conducted to that effect considering the recent rollout of HPV vaccination 
programmes in 2007. Based on immunization guidelines from the CDC and the WHO, the 
doses required to achieve lifelong immunity are dependent upon the type of vaccine used and 





 This review has a number of limitations that would significantly influence the 
generalizability of the findings. The studies included in the final synthesis varied significantly 
in terms of their contexts, perspective, population, costing approaches, and measurement of 
effects employed by the researcher. Most of the included studies were devoid of country-
based data on the age-specific incidence of HPV infections making it impossible to develop 
an accurate model for HPV’s natural history and cervical carcinogenesis.  
Lastly, only one of the included studies used a dynamic model and accounted for the 
potential influence of herd immunity on the cost-effectiveness outcomes. Considering the 
high coverage of vaccination intervention assessed by the included studies, it would be 
prudent to assess the influence that herd immunity exerts on the cost-effectiveness outcomes. 
It is possible that the effects of the interventions that relied on the government perspective 
were overestimated because they did not take into account the costs associated with access to 
services as well as women’s waiting times.  
Conclusions 
 This SR synthesized the existing evidence with regard to the potential cost-
effectiveness of cervical screening and HPV vaccination within the context of LMICs. The 
reviewed evidence suggests that HPV vaccination and screening interventions may be cost-
effective in reducing the lifetime risk, economic burden, and mortality caused by HPV linked 
cervical carcinoma. In addition, combining HPV vaccination with VIA screening has 
potential for better cost-effectiveness outcomes within the context of LMICs in comparison 
with either screening or vaccination only programmes. The cost-effectiveness outcomes of 
HPV vaccination and screening interventions are dependent on age, screening method used, 
intervention coverage, and the number of doses or visits required for vaccination and 




achieved by the different dose schedules of HPV vaccines as well as the inclusion of boys in 
the vaccination programme.    
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Appendix 1: Search strategy (MEDLINE). 
(((((((((developing countries) AND uterine cervical neoplasms)) AND ((hpv OR human 
papillomavirus OR papillomaviridae)))) AND (((((((screen*) OR test*) OR check*) OR 
monitor*) OR triag*)) OR ((("visual inspection") OR cytology) OR ((papanicolaou OR pap 
smear)))))) OR ((((((developing countries) AND uterine cervical neoplasms)) AND ((hpv OR 
human papillomavirus OR papillomaviridae)))) AND (((vaccin*) OR immun*) OR 
innoculat*)))) AND (((((cost-effective* OR cost effective*))) OR ((cost-benefit* OR cost 
benefit*))) OR ((cost-utility OR cost utility))) AND (hasabstract[text] AND 





Appendix 2: Search history (MEDLINE) 
S33 S23 AND S27  Limiters - Date of Publication: 20080101-
20181231; Abstract Available; English 
Language  
Search modes - Boolean/Phrase 
S32  S23 AND S27   Limiters - Date of Publication: 20080101-
20171231; Abstract Available; English 
Language  
Search modes - Boolean/Phrase  
S31  S23 AND S27   Limiters - Abstract Available; English 
Language  
Search modes - Boolean/Phrase  
S30  S23 AND S27   Limiters - Abstract Available; English 
Language  
Search modes - Boolean/Phrase  
S29  S23 AND S27   Limiters - Abstract Available  
Search modes - Boolean/Phrase  
S28  S23 AND S27   Search modes - Boolean/Phrase  
S27  S24 OR S25 OR S26   Search modes - Boolean/Phrase  
S26  cost-utility or cost utility   Search modes - Boolean/Phrase  
S25  cost-benefit* or cost benefit*   Search modes - Boolean/Phrase  
S24  cost-effective* or cost effective*   Search modes - Boolean/Phrase  
S23  S17 OR S22   Search modes - Boolean/Phrase  
S22  S5 AND S21   Search modes - Boolean/Phrase  
S21  S18 OR S19 OR S20   Search modes - Boolean/Phrase  
S20  innoculat*   Search modes - Boolean/Phrase  
S19  immun*   Search modes - Boolean/Phrase  
S18  vaccin*   Search modes - Boolean/Phrase  
S17  S5 AND S16   Search modes - Boolean/Phrase  
S16  S11 OR S15   Search modes - Boolean/Phrase  
S15  S12 OR S13 OR S14   Search modes - Boolean/Phrase  
S14  papanicolaou or papsmear   Search modes - Boolean/Phrase  
S13  cytology   Search modes - Boolean/Phrase  
S12  "visual inspection"   Search modes - Boolean/Phrase  
S11  S6 OR S7 OR S8 OR S9 OR S10   Search modes - Boolean/Phrase  
S10  triag*   Search modes - Boolean/Phrase  
S9  monitor*   Search modes - Boolean/Phrase  
S8  check*   Search modes - Boolean/Phrase  
S7  test*   Search modes - Boolean/Phrase  
S6  screen*   Search modes - Boolean/Phrase  
S5  S3 AND S4   Search modes - Boolean/Phrase  
S4  hpv or human papilomavirus or 
Papillomaviridae   
Search modes - Boolean/Phrase  
S3  S1 AND S2   Search modes - Boolean/Phrase  
S2  (MM "Uterine Cervical Neoplasms")   Search modes - Boolean/Phrase  
S1  (MM "Developing Countries")   Search modes - Boolean/Phrase  
 
 
